Magazine

A team looking to increase efficiency in inventory management among VA medical centers has advice for healthcare facilities.

To make a difference in people’s lives through excellent patient care is both mission and mantra at Banner Health.

Five electrophysiologists joined Cardiovascular Business editorial advisor Matthew R. Reynolds, MD, SM, for a discussion about how they will deliver quality care to a growing number of atrial fibrillation patients even as the U.S. healthcare system turns its focus from volume to value.

Executives from GE Healthcare, McKesson, Merge Healthcare, Philips and Siemens Healthcare joined Cardiovascular Business for a candid discussion about cardiologists’ information technology concerns and questions.

A disconnect between best care and what Medicare is willing to reimburse for it has put some electrophysiologists and their hospitals in a bind.

Will noninferior results be good enough to win over cardiologists and payers?

A new program announced by the ACC will make it possible for the public to access data submitted by hospitals to the National Cardiovascular Data Registry.

Balancing needs, utilization and cost while improving patient care are central to the mission of the interventional cardiology team at Emory Saint Joseph’s Hospital in Atlanta.

Transcatheter aortic valve replacement (TAVR) is proving to be a disruptive technology, as cardiac surgeons and cardiologists join forces and combine resources to determine its ultimate utility.

Despite its name, Bakersfield Heart Hospital offers more service lines than just those under its cardiovascular umbrella.

Every year, more than 795,000 Americans suffer a stroke—with 665,000 people surviving the episode. The annual cost of stroke in the U.S. tops $33.6 billion (Circulation. 2015 ;e29-322.) and one out of six Americans will have a stroke in their lifetime. Stroke is our leading cause of disability.

As the healthcare industry shifts towards a more value-based system, payers, physicians, patients and pharmaceutical companies are paying more attention to the costs and benefits of new treatments. Steven D. Pearson, MD, has been interested in those topics for a long time and has emerged as a leading voice when it comes to comparative effectiveness research and health policy.

Select an Issues